logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Biocare Medical Acquires Empire Genomics, Expanding Molecular Portfolio To Over 1 Million Biomarkers And Adding Rapid Biomarker Development To Lead Cancer Research

Nov 22, 2022•about 3 years ago

Acquiring Company

Biocare Medical

Acquired Company

Empire Genomics, LLC

LondonBuffaloHealth Care

Description

Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.

Company Information

Company

Biocare Medical

Location

London, Ontario, Canada

About

Biocare is a market leader in IHC and molecular diagnostic reagents and instrumentation, including simultaneous Multiplex IHC solutions that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time. The company’s customers include clinical and hospital laboratories, pharmaceutical and biotechnology companies, as well as academic, government, and other research institutions. Biocare offers a comprehensive portfolio of integrated reagents and instrumentation to address the rapidly growing diagnostic and research markets for oncology and immunotherapy. The company is headquartered in Pacheco, CA, and serves customers around the globe. Visit www.biocare.net to learn more.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed